You are here: Industry Insights > GSK

News List

GSK receives positive opinion for triple-therapy inhaler pharmafile
September 18, 2017
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its Trelegy Ellipta treatment for chronic obstructive pulmonary disease (COPD).
FDA panel gives GSK’s Shingrix unanimous approval pharmafile
September 15, 2017
The FDA’s advisory panel has given a strong signal that GSK’s Shingrix should not have too much difficulty getting full FDA approval, after voting swung 11-0 in favour of recommending the vaccine.
GSK's Shingles vaccine gets unanimous recommendation from FDA Panel biospectrumasia
September 15, 2017
A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 for the vaccine for its safety and efficacy
GSK exercises global licence option for Adaptimmune’s NY-ESO-1 T-cell therapy pharmaceufical-technology
September 12, 2017
GlaxoSmithKline (GSK) has exercised the option to obtain an exclusive global licence from Adaptimmune Therapeutics for an investigational SPEAR T-cell receptor therapy targeting NY-ESO-1 (GSK3377794).
GSK makes T-cell move pharmatimes
September 11, 2017
GSK has exercised its option to exclusively license the right to research, develop, and commercialise Adaptimmune's NY-ESO SPEAR T-cell therapy programme, from a collaboration and license agreement signed in 2014.
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO americanpharmaceuticacreview
September 08, 2017
“This is a very exciting day for Adaptimmune as GSK has exercised its option over our NY-ESO program, earlier than originally planned,”
GSK and Propeller expand digital health collaboration biospectrumasiabiospectrumasia
August 30, 2017
In December 2015, Propeller signed on to create a custom sensor for GSK’s Ellipta inhaler, to be used in clinical studies of asthma and COPD
GSK and Propeller expand digital health collaboration biospectrumasia
August 29, 2017
In December 2015, Propeller signed on to create a custom sensor for GSK’s Ellipta inhaler, to be used in clinical studies of asthma and COPD
GSK opens new aluminium salts facility in Scotland pharmatimes.
August 17, 2017
GlaxoSmithKline has officially opened a new £44 million aluminium salts facility in Montrose, Scotland, which is set to supply ingredients for around 400 million vaccines a year
GSK inaugurates its new facility in Scotland biospectrumasia
August 17, 2017
The facility will produce ingredients for vaccines for illnesses such as tetanus, pneumonia and whooping cough

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page